Albert Bourla

Selected news for the person - Albert Bourla, collected since 11/2017. This person shares healthcare news with Pfizer, COVID-19, COVID-19 Vaccine, Coronavirus and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 Pfizer Could Manufacture Up to 100 Million Omicron Vaccine Doses In Spring - TheStreet TheStreet ... testing hybrid combinations of the vaccine to focus on various forms of the coronavirus along with larger doses. These vaccine doses that are targeting the omicron variant are being created “at risk,” CEO Albert Bourla said Monday. Pfizer said it would pay the manufacturing costs if these new doses are not needed or used. Pfizer will be ready to ship out these vaccines targeting omicron if there is a ...
1/12/2022 Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by spring Philly Tribune ... be tweaked for the new threat.Pfizer also is testing hybrid combinations of vaccine to target multiple coronavirus forms, as well as larger doses.The omicron-specific doses will be created "at risk," CEO Albert Bourla said Monday, meaning that if they are not needed, Pfizer will absorb the costs. The company has climbed to the lead in global vaccine production with 3 billion doses in 2021 and is planning ...
1/12/2022 Pfizer plans to produce up to 100 million doses of new Omicron-specific Covid ... mogaznews.com ... million shots of its Omicron specific COVID-19 vaccine between now and the end of spring. The company plans to begin trials for the shots as early as late January (file photo)Pfizer CEO Albert Bourla (pictured) has said that Covid will be around for the next decade, but shots produced by his company may be able to control the virus. His company's shot is already the most popularly used ...
1/12/2022 Pfizer plans to produce up to 100 million doses of new Omicron-specific Covid vaccine by spring expressdigest.com ... million shots of its Omicron specific COVID-19 vaccine between now and the end of spring. The company plans to begin trials for the shots as early as late January (file photo)Pfizer CEO Albert Bourla (pictured) has said that Covid will be around for the next decade, but shots produced by his company may be able to control the virus. His company’s shot is already the most popularly ...
1/11/2022 Pfizer developing vaccine that targets omicron; Chicago set to resume in-person classes: COVID-19 updates Yahoo News Developing a COVID-19 vaccine specifically designed to target the omicron variant is "the most likely scenario," Pfizer's CEO Albert Bourla said Monday as new coronavirus cases exploded to over 700,000 a day in the U.S. on average, obliterating the record set a year ago.Bourla said at the J.P. Morgan Healthcare Conference that Pfizer is developing an omicron-targeted vaccine, in addition to a shot that includes both the ...
1/11/2022 Pfizer developing vaccine that targets omicron; Chicago set to resume in-person classes: COVID-19 updates - NewsBreak newsbreak.com Developing a COVID-19 vaccine specifically designed to target the omicron variant is "the most likely scenario," Pfizer's CEO Albert Bourla said Monday as new coronavirus cases exploded to over 700,000 a day in the U.S. on average, obliterating the record set a year ago.Bourla said at the J.P. Morgan Healthcare Conference that Pfizer is developing an omicron-targeted vaccine, in addition to a shot that includes both the ...
1/11/2022 Pfizer says its COVID-19 vaccine targeting Omicron variant will be ready in March CBS News Pfizer will have a COVID-19 vaccine that specifically targets the Omicron variant ready by March, the pharmaceutical company's chief executive said Monday.Pfizer CEO Albert Bourla said the company has already begun manufacturing a new version of its COVID-19 vaccine that aims to protect recipients against Omicron. "This vaccine will be ready in March," he told CNBC's "Squawk Box" on Monday. "We [are] already starting manufacturing some of ...
1/11/2022 Pfizer CEO says two Covid vaccine doses aren't 'enough for omicron' CNBC Pfizer CEO Albert Bourla on Monday said two doses of the company's vaccine may not provide strong protection against infection from the Covid omicron variant, and the original shots have also lost some of their efficacy at preventing hospitalization. Bourla, in an interview at JPMorgan's health-care conference, emphasized the importance of a third shot to boost people's protection against omicron. "The two doses, they're not enough for omicron," Bourla ...
1/11/2022 Pfizer CEO says two Covid vaccine doses aren’t ‘enough for omicron’ CNBC Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty ImagesPfizer CEO Albert Bourla on Monday said two doses of the company’s vaccine may not provide strong protection against infection from the omicron ...
1/11/2022 Shot targeting omicron may be ready by March, Pfizer predicts McKnight's Long Term Care News ... with a drug that helps build immunity to the highly transmissible variant, Reuters has reported .The company has enough manufacturing capacity to handle production of the new vaccine on a mass scale, Pfizer CEO Albert Bourla said Monday at a healthcare conference. Bourla has previously predicted that most people will need a new vaccine dose by the fall of 2022 as the drug’s efficacy wanes over time, according to ...
1/11/2022 JPM 2022: Pfizer bumps Paxlovid production estimate to 120M for this year while also looking to add more capacity FiercePharma ... it could produce 50 million courses of the treatment in 2022; then, by late in the month, the company bumped that estimate up to 80 million. Monday, during the J.P. Morgan Healthcare Conference, CEO Albert Bourla , Ph.D., took it a big step further.“We have confidence that we can make 120 million treatments this year,” Bourla said. “That’s 3.6 billion tablets. That’s a very big capacity. But ...
1/11/2022 Pfizer CEO: 2 shots 'offer very limited protection, if any': Admits mRNA vaccines don't have 'the safety profile that we hoped' for freerepublic.com 10:05:29 PM PST by SeekAndFindPfizer CEO Albert Bourla acknowledged Monday that two doses of the vaccine his company produces with BioNTech "offer very limited protection, if any" against the dominant omicron variant.Adding a third dose, he said in an interview with Yahoo Finance, provides "reasonable protection against hospitalization and deaths.""Against death, very good (protection), and less protection against infection," the Pfizer chief added.In a separate ...
1/11/2022 Pfizer CEO Bourla says COVID vaccines offer limited protection ‘if any’, adds third dose gives less protection against infection opindia.com Consider reading the article Pfizer CEO Bourla says COVID vaccines offer limited protection ‘if any’, adds third dose gives less protection against infection on OpIndia website ---In an interview with CNBC , Pfizer CEO Albert Bourla stated that two doses of the vaccine give modest protection, if any, whereas three doses with a booster offer reasonable protection against hospitalisation and mortality but less protection against infection. Speaking exclusively to CNBC ...
1/11/2022 Omicron vaccine expected to be ready in March: Pfizer thedailystar.net Pfizer expects a Covid-19 vaccine targeting the Omicron variant to be ready in March, the company's head said Monday.Pfizer Chief Executive Officer Albert Bourla told CNBC that Pfizer is already manufacturing doses due to keen interest from governments, as authorities contend with huge Covid-19 infection counts, including large numbers of "breakthrough" Omicron cases in vaccinated populations."This vaccine will be ready in March," Bourla told the network ...
1/11/2022 Pfizer can prepare Omicron vaccine by March fuentitech.com Technology]Pfizer can prepare Omicron vaccine by Marchglobal: According to researchers at Johns Hopkins University, Covid has killed more than 5.4 million people worldwide, amounting to 5,495,383. On the other hand, the number of infectious diseases has exceeded 300 million, reaching 310,483,235 worldwide.Vaccine drugs and treatmentsAlbert Bourla, Pfizer’s CEO, is likely to need a redesigned Covid-19 vaccine that specifically targets Omicron variants, and his company ...
1/11/2022 Pfizer expects Omicron vaccine to be ready in March samaa.tv Moderna is also developing boosters for OmicronPfizer expects a Covid-19 vaccine targeting the Omicron variant to be ready in March, the company’s head said Monday.Pfizer Chief Executive Officer Albert Bourla told CNBC that Pfizer is already manufacturing doses due to keen interest from governments, as authorities contend with huge Covid-19 infection counts, including large numbers of “breakthrough” Omicron cases in vaccinated populations.“This vaccine ...
1/11/2022 Pfizer CEO Says an Omicron-Targeted Vaccine Will Be Ready in March causeaction.com https://www.theepochtimes.com/pfizer-ceo-says-an-omicron-targeted-vaccine-will-be-ready-in-march_4205221.htmlAlbert Bourla, the CEO of Pfizer, said a COVID-19 vaccine that specifically targets the Omicron variant of the virus as well as already circulating variants “will be ready in March.”“This vaccine will be ready in March. I don’t know how if we will need it, I don’t know how ...
1/11/2022 Pfizer Omicron Vaccine to Be Ready by March, Meta Delays Its Office Return - MarketWatch MarketWatch Pfizer says its Omicron-targeting vaccine should be ready by March. Patrick T. Fallon/AFP via Getty Images Pfizer said it should be able to launch a redesigned Covid-19 vaccine that targets the Omicron variant of the virus by March, while Facebook parent Meta Platforms delayed its U.S. office reopening plans and mandated booster shots for those returning to work.Albert Bourla, chief executive of Pfizer (ticker: PFE ), said ...
1/11/2022 Vaccine for Omicron! Pfizer's new jab likely to be ready by March indianwhitepaper.com Pfizer Inc (PFE.N) Chief Executive Albert Bourla said on Monday that moving toward a redesigned COVID-19 vaccine that is specifically targeted to combat the Omicron variant of the coronavirus is the “most likely scenario”, reported Reuters.Speaking at the J.P. Morgan Healthcare Conference, Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine variant as well as a shot that would include both ...
1/11/2022 Pfizer Omicron Vaccine to Be Ready by March, Meta Delays Its Office Return | Barron's barrons.com Pfizer said it should be able to launch a redesigned Covid-19 vaccine that targets the Omicron variant of the virus by March, while Facebook parent Meta Platforms delayed its U.S. office reopening plans and mandated booster shots for those returning to work.Albert Bourla, chief executive of Pfizer (ticker: PFE), said Monday the pharmaceutical company and its partner BioNTech (BNTX) already had started manufacturing a version of the vaccine ...